文献速递真菌感染医院感染防控

低剂量脂质体两性霉素B在儿童异基因造血干细胞移植中抗真菌预防

Low-dose liposomal amphotericin B for antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell transplantation.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该回顾性观察研究纳入2012至2016年间118例接受异基因造血干细胞移植的儿童患者(共125例次移植),评估静脉低剂量脂质体两性霉素B(1 mg/kg/天)在植入前阶段作为初级抗真菌预防的有效性和安全性。结果显示突破性侵袭性真菌感染发生率为7.7%,均为高危患者,不良事件均为I级且发生率20%,30天总生存率99.2%。表明该方案可能安全有效,即使对高危儿童。

要点

  • 低剂量L-AmB(1 mg/kg/天)在儿童HSCT植入前预防中突破性IFI发生率为7.7%。
  • 不良事件均为I级,发生率20%,仅1例需停药。
  • 巨细胞病毒共感染是IFI唯一有统计学意义的危险因素。

核心结论

  • 低剂量L-AmB(1 mg/kg/天)用于儿童异基因HSCT植入前初级抗真菌预防,突破性IFI发生率与既往报道相当,显著毒性发生率极低,可能为安全有效的选择,甚至适用于高危患者。

研究设计与样本

  • 回顾性观察性研究,纳入2012年1月至2016年12月期间所有连续接受HSCT且年龄≤18岁、使用静脉L-AmB(1 mg/kg/天,从-1天至出院前48小时)进行抗真菌预防的患者,共125例次移植(118例患者),中位年龄7.2岁(IQR 4.2-11.5)。

主要发现

  • 125例次移植中,血液系统恶性肿瘤为主要基础疾病(63.6%),109例(87.2%)被认为存在侵袭性真菌感染高危风险。
  • 10例患者(7.7%)发生突破性IFI(3例念珠菌属,7例侵袭性霉菌感染),均为高危患者,且总体死亡率有升高趋势。
  • IFI唯一有统计学意义的危险因素是巨细胞病毒共感染。
  • 不良事件均为I级,发生于25例(20%),仅1例需停用L-AmB。
  • 30天总生存率为99.2%;研究结束时,1例患者死于IFI。

临床怎么用

  • 对于儿童异基因HSCT植入前阶段,尤其是高危患者,可考虑使用低剂量L-AmB(1 mg/kg/天)作为初级抗真菌预防,需注意巨细胞病毒共感染者的IFI风险。

局限性

  • 回顾性观察性设计,样本量有限,未设对照组,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary antifungal prophylaxis in paediatric allogeneic HSCT recipients is mainly based on azoles, which can have related toxicity and drug interactions. Low-dose liposomal amphotericin B (L-AmB) is an attractive intravenous alternative because of its low toxicity and lower risk of interactions. OBJECTIVES: To evaluate the effectiveness and safety of L-AmB (1 mg/kg/day) for primary antifungal prophylaxis in pre-engraftment paediatric HSCT patients. PATIENTS AND METHODS: Retrospective, observational study including all consecutive patients aged ≤18 years who underwent HSCT and received antifungal prophylaxis with intravenous L-AmB (1 mg/kg/day, from day -1 to 48 h before discharge) between January 2012 and December 2016. RESULTS: In total, 125 HSCT procedures in 118 patients were included, median age 7.2 years (IQR 4.2-11.5). Haematological malignancies were the main underlying condition (63.6%), and 109 (87.2%) were considered at high risk for invasive fungal infection (IFI). Ten patients (7.7%), all high risk, developed breakthrough IFI (three Candida spp., seven invasive mould infections) and tended to have higher overall mortality. The only statistically significant risk factor for IFI was cytomegalovirus co-infection. Adverse events, all grade I, occurred in 25 (20%), requiring L-AmB withdrawal in one case. Overall survival at 30 days was 99.2%. At study completion, one patient had died of IFI. CONCLUSIONS: The incidence of breakthrough IFI was comparable to that of previous reports, with a very low rate of significant toxicity. Thus, prophylactic L-AmB may be a safe, effective option for antifungal prophylaxis in the pre-engraftment phase for children undergoing HSCT, even those at high risk.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mendoza-Palomar N, Soques E, Benitez-Carabante MI, et al. Low-dose liposomal amphotericin B for antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell transplantation. J Antimicrob Chemother. 2020. PMID: 32335674. doi:10.1093/jac/dkaa149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。